FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL							
OMB Number: 3235-028							
Estimated average burden							
hours per response:	0.5						

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name a DIXON (Last) C/O ENZ 685 ROU (Street) BRIDGE	enzn 3. Dat 09/30	2. Issuer Name and Ticker or Trading Symbol ENZON PHARMACEUTICALS INC [ enzn ]  3. Date of Earliest Transaction (Month/Day/Year) 09/30/2003  4. If Amendment, Date of Original Filed (Month/Day/Year)								Relationship of Reporting Person(s) to Issuer heck all applicable)  X Director 10% Owner Officer (give title below)  Individual or Joint/Group Filing (Check Applicable he)  X Form filed by One Reporting Person Form filed by More than One Reporting Person									
(Oity)			Zip) Ie I - N	on-Deriv	/ative S	Sec	uritie	es Ac	quired,	Disp	osed of	, or Ber	eficiall	ficially Owned					
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day					ction	ion 2A. Deemed Execution Date,			3. Transac	3. 4. Securit Transaction Code (Instr. 8) 4. Securit Disposed and 5)		ties Acquired (A) or I Of (D) (Instr. 3, 4		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		'. Nature of Indirect Beneficial Dwnership Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date,		4. Transaction Code (Instr. 8)		Number		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Inst and 4)		8. Price of Derivative Security (Instr. 5)	9. Number o derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)		Ownership Form: Direct (D) or Indirect (I) (Instr.	Beneficial Ownership	
					Code	v	(A)	(D)	Date Exercisable		piration tte	Title	Amount or Number of Shares						
Common Stock Right <sup>(1)</sup>	\$0 <sup>(2)</sup>	09/30/2003			A		301		01/01/2004 <sup>(</sup>	1) 06.	/30/2004 <sup>(1)</sup>	Common Stock	301	\$0	301		D		

## **Explanation of Responses:**

1. Securities granted by Enzon Pharmaceuticals, Inc. pursuant to Enzon's 2001 Incentive Stock Plan as compensation for service as an Independent Director during the quarter ended September 30, 2003 and qualified under Rule 16b-3(d). The value of the compensation was \$3,500. In the spring of 2004, each Common Stock right will be exchanged for one share of Common Stock; provided, however, Ms. Dixon will be entitled to elect to receive cash for up to 50% of these rights, with the price per right being \$11.64, the fair market value of Enzon's common stock on September 30, 2003.

2. On a 1-for-1 basis.

/s/ Kenneth J. Zuerblis (Attorney in Fact) 10/02/2003

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.